Marketing


  • Pill gavel
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    On second try, Acadia drug gets nod from European regulators

    The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.

    By June 26, 2026
  • Medicine pill on 100 dollar banknote background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Hospitals irate after Eli Lilly follows through on 340B ultimatum

    The drugmaker stopped paying 340B discounts to hospitals that didn’t comply with its new paperwork requirements late last week. Hospitals are urging HRSA to step in.

    By Rebecca Pifer Parduhn • June 23, 2026
  • A stylized illustration of a pill breaking apart into smaller pills. Explore the Trendline
    Image attribution tooltip
    Brian Tucker / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Trendline

    Commercialization

    New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.

    By BioPharma Dive staff
  • A collage of six photos showing a woman at different life stages
    Image attribution tooltip

    Woven Health Collective via Envato / AI-supported editing

    Image attribution tooltip
    Sponsored by Woven Health Collective

    From episodes to a lifetime: How AI can enable women’s health brands to build a partnership that lasts

    Women's health audiences have long memories and finely tuned instincts for what is performative.

    By Jennifer M. Barrett, MSc • June 22, 2026
  • Promotional graphic for Season 2 of The Progress Profile: Alzheimer’s Research in Focus, featuring the Pearson and BioPharma Dive logos on a dark blue background with abstract glowing blue wave patterns on the right.
    Image attribution tooltip
    William Walker/BioPharma Dive
    Image attribution tooltip
    Sponsored by Pearson

    [Podcast] (Season 2) The Progress Profile: Alzheimer’s Research in Focus

    This podcast explores how leading Alzheimer’s experts are working to bridge the gap between clinical trial design and frontline care.

    By BioPharma Dive's studioID • June 16, 2026
  • A piece of paper with the word "Medicare" emblazoned on a blue background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Medicare drug price rule may target under-the-skin Keytruda and Opdivo

    For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.

    By June 15, 2026
  • The outside of the U.S. Supreme Court with blue sky and clouds in the background.
    Image attribution tooltip
    Fintan Trimble via Getty Images
    Image attribution tooltip

    Generic drugmakers gain key victory in ‘skinny label’ patent case

    The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.

    By June 5, 2026
  • A sign with Eli Lilly's logo sits outside of the company's headquarters on March 17, 2024 in Indianapolis.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Eli Lilly issues data sharing ultimatum to 340B hospitals

    Select hospitals have refused to share data to prove they’re not double-dipping drug discounts, Lilly said. Hospitals, which have until Monday to comply, are urging the government to intervene.

    By Rebecca Pifer Parduhn • June 2, 2026
  • A pill bottle for Eli Lilly's oral weight loss medication Foundayo
    Image attribution tooltip
    Courtesy of Eli Lilly
    Image attribution tooltip
    Obesity drugs

    CVS obesity drug deal puts Lilly on equal footing with Novo

    The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk. 

    By Kristin Jensen • May 28, 2026
  • A pill bottle for Eli Lilly's oral weight loss medication Foundayo
    Image attribution tooltip
    Courtesy of Eli Lilly
    Image attribution tooltip

    FDA asks Lilly to evaluate obesity pill’s liver risk

    The request, which is part of a just-released approval letter for Foundayo, comes amid an intensifying marketing battle between Lilly and Novo.

    By April 15, 2026
  • Signs for Johnson & Johnson are seen on company offices in California.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J leans on Tremfya, cancer drugs to overcome Stelara losses

    A growing multiple myeloma franchise helped the pharmaceutical giant top Wall Street’s expectations and surpass $15 billion in first-quarter drug sales.

    By April 14, 2026
  • A pill bottle for Eli Lilly's oral weight loss medication Foundayo
    Image attribution tooltip
    Courtesy of Eli Lilly
    Image attribution tooltip
    Obesity drugs

    Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk

    After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, where Novo has a three-month lead.

    By Kristin Jensen • April 9, 2026
  • Hims & Hers Super Bowl ad header
    Image attribution tooltip
    Courtesy of Hims & Hers
    Image attribution tooltip

    Hims & Hers says limited data stolen in social engineering attack

    The telehealth provider said hackers gained access to a third-party customer service platform, but medical records remained secure.

    By David Jones • April 6, 2026
  • A sign with Eli Lilly's logo sits outside of the company's headquarters on March 17, 2024 in Indianapolis.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    FDA approves Lilly obesity pill, triggering battle with Novo Nordisk

    Foundayo could erase the Wegovy pill’s four-month head start as the two drugmakers clash on a debate of efficacy and convenience.

    By April 1, 2026
  • Makary FDA
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip

    New FDA guidance could elevate pharma’s biosimilar market

    Biologic copycats have had a limited impact on U.S. drug prices so far, but loosening regulatory restrictions could help accelerate their progress. 

    By Michael Gibney • March 13, 2026
  • A sign with Eli Lilly's logo sits outside of the company's headquarters on March 17, 2024 in Indianapolis.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders

    Lilly asked the FDA to step in after claiming that testing it’s done suggests copycat versions of Zepbound may carry “unknown risks.”

    By March 12, 2026
  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip
    Trump administration

    FDA clears repurposed GSK drug for ultra-rare brain disease instead of autism

    Months after promising help for “hundreds of thousands of kids,” the FDA approved the decades-old medicine for a disease documented in less than 50 people.

    By Kristin Jensen • March 11, 2026
  • Hims & Hers Super Bowl ad header
    Image attribution tooltip
    Courtesy of Hims & Hers
    Image attribution tooltip
    Obesity drugs

    Novo, Hims reach deal to sell GLP-1 drugs together

    The agreement ends a messy dispute that began when the telehealth firm attempted to sell a compounded form of Novo’s Wegovy pill at a cheaper price. 

    By March 9, 2026
  • An illustration of immune system T cells attacking cancer cells.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    FDA issues speedy approval to J&J’s Tecvayli-Darzalex combo

    The regimen’s clearance in early multiple myeloma was the third approval under the agency’s controversial “national priority” voucher program and issued only 55 days after the review began.

    By March 6, 2026
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly targets employers in new bid to broaden access to obesity drugs

    A service tailored to people with workplace-based insurance coverage represents a new way for Lilly to bypass insurers and expand use of its popular obesity shot. 

    By March 5, 2026
  • A Lilly sign is seen on the side of a building viewed through pine trees
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial

    Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates. 

    By Feb. 26, 2026
  • A sign bearing the logo for the Centers for Disease Control and Prevention stands outside of an office building.
    Image attribution tooltip
    Elijah Nouvelage via Getty Images
    Image attribution tooltip
    Vaccines

    15 states sue HHS over changes to childhood vaccine schedule

    The lawsuit seeks to reverse the abrupt overhaul of the U.S. immunization schedule as well as the federal government’s allegedly “unlawful” reformation of a key vaccine panel.

    By Feb. 25, 2026
  • Vertex
    Image attribution tooltip
    Permission granted by Vertex
    Image attribution tooltip

    Vertex’s CRISPR therapy rebounds in latest earnings

    Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter, a performance analysts saw as a bright spot in Vertex's report.

    By Feb. 13, 2026
  • A sign at Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip

    Gilead dips as ‘strong’ earnings outweighed by high expectations for new HIV drug

    Shares fell as much as 6% in after-hours trading, a decline one analyst guessed may be because Yeztugo’s trajectory isn’t matching investors’ sky-high hopes.

    By Feb. 10, 2026
  • Engraving on a wall reads "wall street."
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip
    News roundup

    Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myers’ waiting game

    Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie franchise and Bristol Myers pointed to a trio of narrative-changing trials.

    By BioPharma Dive staff • Feb. 5, 2026
  • Hims & Hers Super Bowl ad header
    Image attribution tooltip
    Courtesy of Hims & Hers
    Image attribution tooltip
    Obesity drugs

    Novo, Lilly sputter as Hims launches knockoff GLP-1 pill

    Novo is threatening litigation in response, while FDA head Martin Makary, without naming specific companies, said the agency would take “swift action” against those “mass-marketing illegal copycat drugs.”  

    By Updated Feb. 6, 2026